TY  - JOUR
AU  - Baertsch, Marc-Andrea
AU  - Mai, Elias K
AU  - Hielscher, Thomas
AU  - Bertsch, Uta
AU  - Salwender, Hans J
AU  - Munder, Markus
AU  - Fuhrmann, Stephan
AU  - Dührsen, Ulrich
AU  - Brossart, Peter
AU  - Neben, Kai
AU  - Schlenzka, Jana
AU  - Kunz, Christina
AU  - Raab, Marc S
AU  - Hillengaß, Jens
AU  - Jauch, Anna
AU  - Seckinger, Anja
AU  - Hose, Dirk
AU  - Luntz, Steffen
AU  - Sonneveld, Pieter
AU  - Lokhorst, Henk
AU  - Martin, Hans
AU  - Goerner, Martin
AU  - Hoffmann, Martin
AU  - Lindemann, Hans-Walter
AU  - Bernhard, Helga
AU  - Blau, Igor W
AU  - Scheid, Christof
AU  - Besemer, Britta
AU  - Weisel, Katja C
AU  - Hänel, Mathias
AU  - Dürig, Jan
AU  - Goldschmidt, Hartmut
TI  - Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
JO  - Blood cancer journal
VL  - 11
IS  - 1
SN  - 2044-5385
CY  - London [u.a.]
PB  - Nature Publishing Group
M1  - DKFZ-2021-00064
SP  - 1
PY  - 2021
AB  - Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m2 i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1-21 of 28 day cycles) followed by 10-15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91
LB  - PUB:(DE-HGF)16
C6  - pmid:33414374
DO  - DOI:10.1038/s41408-020-00390-3
UR  - https://inrepo02.dkfz.de/record/166717
ER  -